HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congress Targets Sequester-Proof User Fees For FDA

This article was originally published in The Tan Sheet

Executive Summary

Rep. Sam Farr says Congressional Budget Office scoring problems prevent releasing FDA’s fiscal 2013 user fees from being held in the budget sequester, but an amendment will be proposed to ensure the agency’s fiscal 2014 fees are included in its appropriations.

You may also be interested in...



FDA Budget Could Face 5% Cut In Fiscal 2015

An Office of Management and Budget memo says federal agencies should reduce net discretionary spending from the initial fiscal 2015 estimate and provide options for additional cuts. Across-the-board cuts and “new user fees to offset existing spending” are not allowed in fiscal 2015 requests.

New Food And Drug User Fees Face Long Odds In Congress

FDA’s $4.7 billion fiscal 2014 budget request proposes new fees including $58.9 million from food establishment registrations and inspections, $19.1 million from cosmetics firms and $15.04 million from medical product reinspections.

FDA “People Power” Could Take Sequestration Hit – Hamburg

The FDA commissioner says a budget sequester would slow implementation of FDA Safety and Innovation Act provisions and reduce some overseas inspections. More emphasis could be placed on using systems that target the riskiest facilities to reduce the number of onsite inspections, Hamburg says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124192

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel